Expression of SOCS3 mRNA in bone marrow cells from CML patients associated with cytogenetic response to IFN-alpha

Kazuto Takeuchi; Ikuya Sakai; Hirosi Narumi; Masaki Yasukawa; Kensuke Kojima; Yoko Minamoto; Tomoaki Fujisaki; Kazushi Tanimoto; Masamichi Hara; Akihiko Numata; Hisashi Gondo; Masuhiro Takahashi; Nobuharu Fujii; Kozo Masuda; Shigeru Fujita

doi:10.1016/j.leukres.2004.06.006

Expression of SOCS3 mRNA in bone marrow cells from CML patients associated with cytogenetic response to IFN-alpha

Leuk Res. 2005 Feb;29(2):173-8. doi: 10.1016/j.leukres.2004.06.006.

Authors

Kazuto Takeuchi¹, Ikuya Sakai, Hirosi Narumi, Masaki Yasukawa, Kensuke Kojima, Yoko Minamoto, Tomoaki Fujisaki, Kazushi Tanimoto, Masamichi Hara, Akihiko Numata, Hisashi Gondo, Masuhiro Takahashi, Nobuharu Fujii, Kozo Masuda, Shigeru Fujita

Affiliation

¹ First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime 791-0295, Japan.

PMID: 15607366
DOI: 10.1016/j.leukres.2004.06.006

Abstract

Previously, we have demonstrated that constitutive expression of suppressor of cytokine signaling-3 (SOCS3) affects the sensitivity of chronic myelogenous leukemia (CML) cell lines to interferon-alpha (IFN-alpha). In the present study, we analyzed the expression of SOCS3 mRNA in bone marrow cells from patients with CML at diagnosis, with the aid of real-time polymerase chain reaction. SOCS3 mRNA expression in bone marrow cells from CML patients who responded well to IFN-alpha therapy was significantly lower than that in cells from healthy volunteers and patients who were resistant to IFN-alpha therapy. Methylation of SOCS3 promoter was absent in bone marrow cells from all CML patients examined. These results indicate that the expression of SOCS3 mRNA is inversely associated with the sensitivity to IFN-alpha both in vitro and in vivo and that differences in SOCS3 mRNA expression are not due to the methylation status of SOCS3 promoters.

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Bone Marrow Cells / cytology*
Bone Marrow Cells / drug effects*
Bone Marrow Cells / metabolism
Gene Expression Regulation, Leukemic / drug effects
Humans
Interferon-alpha / therapeutic use*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
Methylation
RNA, Messenger / analysis
RNA, Messenger / drug effects
RNA, Messenger / genetics*
Repressor Proteins / analysis
Repressor Proteins / drug effects
Repressor Proteins / genetics*
Sensitivity and Specificity
Suppressor of Cytokine Signaling 3 Protein
Suppressor of Cytokine Signaling Proteins
Transcription Factors / analysis
Transcription Factors / drug effects
Transcription Factors / genetics*

Substances

Interferon-alpha
RNA, Messenger
Repressor Proteins
SOCS3 protein, human
Suppressor of Cytokine Signaling 3 Protein
Suppressor of Cytokine Signaling Proteins
Transcription Factors